A.R.T. Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

A.R.T. Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,600	Closed	-$657K	–	1336
2017 Q3	$657K	Sell	5,600 -44,900	-89%	-$3.83M	0.03%	718
2017 Q2	$4.03M	Buy	50,500 +42,300	+516%	+$2.7M	0.21%	101
2017 Q1	$420K	Sell	8,200 -34,500	-81%	-$1.59M	0.02%	870
2016 Q4	$1.6M	Buy	+42,700	New	+$1.79M	0.1%	337
2016 Q3	–	Sell	-29,084	Closed	-$1.61M	–	644
2016 Q2	$1.61M	Sell	29,084 -3,900	-12%	-$246K	0.08%	379
2016 Q1	$2.07M	Buy	+32,984	New	+$2.19M	0.09%	322
2015 Q4	–	Sell	-10,891	Closed	-$875K	–	1442
2015 Q3	$875K	Sell	10,891 -10,113	-48%	-$1.12M	0.03%	670
2015 Q2	$2.52M	Sell	21,004 -11,294	-35%	-$1.35M	0.08%	367
2015 Q1	$3.37M	Buy	32,298 +21,946	+212%	+$2.22M	0.12%	239
2014 Q4	$1M	Buy	+10,352	New	+$959K	0.04%	643
2014 Q2	–	Sell	-11,349	Closed	-$761K	–	1287
2014 Q1	$761K	Buy	+11,349	New	+$879K	0.04%	595
2013 Q4	–	Sell	-121,215	Closed	-$7.76M	–	1252
2013 Q3	$7.76M	Buy	121,215 +9,755	+9%	+$486K	0.42%	20
2013 Q2	$3.46M	Buy	+111,460	New	+$2.97M	0.11%	254

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BRC

Blue Ridge Capital New York $215M AUM

A.R.T. Advisors's ALNY Position: Q4 2017 in Review

A.R.T. Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2017, closing a stake of 5,600 shares — an estimated $657K sold.

A.R.T. Advisors first reported a position in ALNY in Q2 2013 and held it in 13 quarters. The position peaked at $7.76M in Q3 2013. 282 funds tracked by Wall St. Rank hold ALNY as of Q4 2017.

A.R.T. Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
A.R.T. Advisors sold 5,600 Alnylam Pharmaceuticals shares in Q4 2017, an estimated $657K.
A.R.T. Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 13 quarters.
A.R.T. Advisors's Alnylam Pharmaceuticals position peaked at $7.76M in Q3 2013.
282 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2017.

Based on A.R.T. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.